Slide 1 of 42 IAS–USA AU EDITED FINAL: 03-18-13 Julio Montaner, MD Professor of Medicine, and...
-
Upload
johnathan-glenn -
Category
Documents
-
view
216 -
download
1
Transcript of Slide 1 of 42 IAS–USA AU EDITED FINAL: 03-18-13 Julio Montaner, MD Professor of Medicine, and...
Slide 1 of 42
IAS–USAAU EDITED FINAL: 03-18-13
Julio Montaner, MDProfessor of Medicine, and Head, Div. of AIDS, University of British Columbia
Director, BC-Centre for Excellence in HIV/AIDS at Providence Health CarePast President, International AIDS Society (2008-2010)
Treatment as Prevention:The Key to an AIDS-Free Generation
Slide 2 of 44
January 2004
Summer of 1996
Year
Summer of 2000
Phase I Phase II Phase III
Montaner et al, Lancet, 2010
Increasing HAART Coverage within Evolving Guidelines in BC
N = 7492 by the end of 2011
Slide 3 of 44
Pre-HAART CD4 counts in BCby year, 2003-2012
Lima et al, in preparation, 2013
Slide 4 of 44
Adherence to HAART in BCby year, 1996-2012
Lima et al, in preparation, 2013
Slide 5 of 44
Slide 6 of 44HIV Drug Resistance in BC
by year, 1996-2012
Lima et al, in preparation, 2013
Slide 7 of 44
BC: All Cause Mortality (#)
0
50
100
150
200
250
300
350
400
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Years
Freq
uenc
y
> 90% Decrease in All Cause Mortality among HIV Infected Individuals in BC since 1996
Montaner et al, TasP Workshop, April 2012
Slide 8 of 44AIDS New Cases for BC by year, 1996-2011
Lima et al, in preparation, 2013
Slide 9 of 44
BC: HIV Prevalence and TB Incidence
James Johnston, WIP, May 2013
Slide 10 of 44HAART Use & New HIV Diagnoses for BC by year, 1996-2012
Lima et al, in preparation, 2013
HIV Incidence
Active on HAART
New HIV Diagnoses (All)
New HIV Diagnoses (Ever IDU)
Slide 11 of 44Annual rates (per 100,000 population) for new cases of genital chlamydia, genital gonorrhea, infectious syphilis and
hepatitis C, 1996-2012
Lima et al, in preparation, 2013
Hepatitis C Syphilis
GonorrheaChlamydia
Slide 12 of 44
Programmatic Compliance Score Assesses the impact of non-
compliance with HIV treatment guidelines on all-cause mortality
PCS components include: Baseline CD4 > 200/mm3 Three CD4 in 1st year Three VL in 1st year Baseline resistance Recommended HAART Undetectable pVL at 9 months
Failure to meet a given component add one to the score
PCS predicts mortality
Lima et al. PLoS ONE 7(11): e47859. 2012
Slide 13 of 44
PCS in BC 2000 to 2011
Lima et al, in preparation, 2013
Slide 14 of 44
R Lester, M Morshed, and M Gilbert, BCMJ, May 4th 2013
Slide 15 of 44
red = drug resistance at
baselinenode size = date
of baseline sample
Slide 16 of 44
HIV Diagnoses by Region and YearPublic Health Agency of Canada
Link4th Intl HIV TREATMANT AS PREVENTION Workshop
April 1st to 4th 2014 - Vancouver, BC, Canada.
Slide 19 of 44
In Collaboration with PHC, VCHA, NHA, PHSA, Community, and MoH